{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:21:45Z","timestamp":1790799705234,"version":"4.1.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10993-3","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:26:10Z","timestamp":1758893170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Unlocking the role of transcription activator-like effector nuclease (TALENs) and zinc finger nuclease (ZFN) in the treatment of HIV"],"prefix":"10.1007","volume":"52","author":[{"given":"Akmal","family":"Zubair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saed Ayidh","family":"Althobaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"8","key":"10993_CR1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrd1151","volume":"2","author":"A Carr","year":"2003","unstructured":"Carr A (2003) Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2(8):624\u2013634","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10993_CR2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.aids.0000174455.01369.ad","volume":"19","author":"M Zaccarelli","year":"2005","unstructured":"Zaccarelli M et al (2005) Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 19(10):1081\u20131089","journal-title":"AIDS"},{"issue":"3","key":"10993_CR3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11262-025-02149-z","volume":"61","author":"A Zubair","year":"2025","unstructured":"Zubair A et al (2025) Molecular characterization and drug resistance pattern in pol gene of HIV-1 sub-subtypes circulating in Lahore, Pakistan. Virus Genes 61(3):324\u2013341","journal-title":"Virus Genes"},{"issue":"6","key":"10993_CR4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/hiv.70024","volume":"26","author":"A Zubair","year":"2025","unstructured":"Zubair A et al (2025) mRNA vaccines against HIV: hopes and challenges. HIV Med 26(6):824\u2013838","journal-title":"HIV Med"},{"issue":"6","key":"10993_CR5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","volume":"9","author":"JD Siliciano","year":"2003","unstructured":"Siliciano JD et al (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4\u2009+\u2009t cells. Nat Med 9(6):727\u2013728","journal-title":"Nat Med"},{"issue":"3\u20134","key":"10993_CR6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cbpa.2012.06.007","volume":"16","author":"P Perez-Pinera","year":"2012","unstructured":"Perez-Pinera P, Ousterout DG, Gersbach CA (2012) Advances in targeted genome editing. Curr Opin Chem Biol 16(3\u20134):268\u2013277","journal-title":"Curr Opin Chem Biol"},{"issue":"3","key":"10993_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/COH.0b013e32835f736c","volume":"8","author":"D Stone","year":"2013","unstructured":"Stone D, Kiem H-P, Jerome KR (2013) Targeted gene disruption to cure HIV. Curr Opin HIV AIDS 8(3):217\u2013223","journal-title":"Curr Opin HIV AIDS"},{"issue":"5283","key":"10993_CR8","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1126\/science.273.5283.1856","volume":"273","author":"M Dean","year":"1996","unstructured":"Dean M et al (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273(5283):1856\u20131862","journal-title":"Science"},{"issue":"3","key":"10993_CR9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","volume":"86","author":"R Liu","year":"1996","unstructured":"Liu R et al (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86(3):367\u2013377","journal-title":"Cell"},{"issue":"6593","key":"10993_CR10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","volume":"382","author":"M Samson","year":"1996","unstructured":"Samson M et al (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382(6593):722\u2013725","journal-title":"Nature"},{"issue":"10","key":"10993_CR11","first-page":"2791","volume":"117","author":"K Allers","year":"2011","unstructured":"Allers K et al (2011) Evidence for the cure of HIV infection by CCR5\u220632\/\u220632 stem cell transplantation. Blood J Am Soc Hematol 117(10):2791\u20132799","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"10993_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/QAD.0b013e328340fe28","volume":"25","author":"G H\u00fctter","year":"2011","unstructured":"H\u00fctter G, Thiel E (2011) Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient 2. AIDS 25(2):273\u2013274","journal-title":"AIDS"},{"issue":"2","key":"10993_CR13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14712590903448158","volume":"10","author":"S Subramanya","year":"2010","unstructured":"Subramanya S et al (2010) RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic SiRNA or vector-based shrna?? Expert Opin Biol Ther 10(2):201\u2013213","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10993_CR14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0092-8674(87)90646-5","volume":"51","author":"KR Thomas","year":"1987","unstructured":"Thomas KR, Capecchi MR (1987) Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51(3):503\u2013512","journal-title":"Cell"},{"issue":"6287","key":"10993_CR15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/346847a0","volume":"346","author":"KR Thomas","year":"1990","unstructured":"Thomas KR, Capecchi MR (1990) Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature 346(6287):847\u2013850","journal-title":"Nature"},{"issue":"6197","key":"10993_CR16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/336348a0","volume":"336","author":"SL Mansour","year":"1988","unstructured":"Mansour SL, Thomas KR, Capecchi MR (1988) Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 336(6197):348\u2013352","journal-title":"Nature"},{"key":"10993_CR17","doi-asserted-by":"crossref","unstructured":"The knockout mouse project. Nat Genet, (2004) 36(9): p. 921\u2013924","DOI":"10.1038\/ng0904-921"},{"issue":"1","key":"10993_CR18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nmeth.1805","volume":"9","author":"M Isalan","year":"2012","unstructured":"Isalan M (2012) Zinc-finger nucleases: how to play two good hands. Nat Methods 9(1):32\u201334","journal-title":"Nat Methods"},{"key":"10993_CR19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ggedit.2021.100007","volume":"2","author":"S Becker","year":"2021","unstructured":"Becker S, Boch J (2021) TALE and TALEN genome editing technologies. Gene and Genome Editing 2:100007","journal-title":"Gene and Genome Editing"},{"issue":"2","key":"10993_CR20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1534\/genetics.110.120717","volume":"186","author":"M Christian","year":"2010","unstructured":"Christian M et al (2010) Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186(2):757\u2013761","journal-title":"Genetics"},{"issue":"2","key":"10993_CR21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt.1755","volume":"29","author":"JC Miller","year":"2011","unstructured":"Miller JC et al (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29(2):143\u2013148","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10993_CR22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jplph.2005.12.001","volume":"163","author":"S Schornack","year":"2006","unstructured":"Schornack S et al (2006) Gene-for-gene-mediated recognition of nuclear-targeted AvrBs3-like bacterial effector proteins. J Plant Physiol 163(3):256\u2013272","journal-title":"J Plant Physiol"},{"issue":"5850","key":"10993_CR23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1126\/science.1144958","volume":"318","author":"P R\u00f6mer","year":"2007","unstructured":"R\u00f6mer P et al (2007) Plant pathogen recognition mediated by promoter activation of the pepper Bs3 resistance gene. Science 318(5850):645\u2013648","journal-title":"Science"},{"issue":"5959","key":"10993_CR24","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1178811","volume":"326","author":"J Boch","year":"2009","unstructured":"Boch J et al (2009) Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326(5959):1509\u20131512","journal-title":"Science"},{"issue":"3","key":"10993_CR25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.32607\/20758251-2014-6-3-19-40","volume":"6","author":"A Nemudryi","year":"2014","unstructured":"Nemudryi A et al (2014) TALEN and crispr\/cas genome editing systems: tools of discovery. Acta Naturae 6(3):19\u201340","journal-title":"Acta Naturae"},{"key":"10993_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40778-014-0008-7","volume":"1","author":"K Bloom","year":"2015","unstructured":"Bloom K, Mussolino C, Arbuthnot P (2015) Transcription activator-like effector (TALE) nucleases and repressor TALEs for antiviral gene therapy. Curr Stem Cell Rep 1:1\u20138","journal-title":"Curr Stem Cell Rep"},{"issue":"1","key":"10993_CR27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev-phyto-080508-081936","volume":"48","author":"J Boch","year":"2010","unstructured":"Boch J, Bonas U (2010) Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu Rev Phytopathol 48(1):419\u2013436","journal-title":"Annu Rev Phytopathol"},{"issue":"1","key":"10993_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","volume":"14","author":"JK Joung","year":"2013","unstructured":"Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49\u201355","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5959","key":"10993_CR29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.1178817","volume":"326","author":"MJ Moscou","year":"2009","unstructured":"Moscou MJ, Bogdanove AJ (2009) A simple cipher governs DNA recognition by TAL effectors. Science 326(5959):1501\u20131501","journal-title":"Science"},{"issue":"5","key":"10993_CR30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nmeth.3330","volume":"12","author":"JC Miller","year":"2015","unstructured":"Miller JC et al (2015) Improved specificity of TALE-based genome editing using an expanded RVD repertoire. Nat Methods 12(5):465\u2013471","journal-title":"Nat Methods"},{"issue":"6069","key":"10993_CR31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1126\/science.1215670","volume":"335","author":"D Deng","year":"2012","unstructured":"Deng D et al (2012) Structural basis for sequence-specific recognition of DNA by TAL effectors. Science 335(6069):720\u2013723","journal-title":"Science"},{"issue":"17","key":"10993_CR32","doi-asserted-by":"crossref","first-page":"8920","DOI":"10.1128\/JVI.00052-12","volume":"86","author":"JT Schiffer","year":"2012","unstructured":"Schiffer JT et al (2012) Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 86(17):8920\u20138936","journal-title":"J Virol"},{"issue":"2","key":"10993_CR33","first-page":"507","volume":"45","author":"AS Lok","year":"2007","unstructured":"Lok AS, McMahon BJ (2007) Chronic Hepat B Hepatol 45(2):507\u2013539","journal-title":"Chronic Hepat B Hepatol"},{"issue":"2","key":"10993_CR34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/mt.2013.212","volume":"22","author":"J Chen","year":"2014","unstructured":"Chen J et al (2014) An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther 22(2):303\u2013311","journal-title":"Mol Ther"},{"key":"10993_CR35","unstructured":"HIV W (2019) AIDS data and statistics. WHO. World Health Organization"},{"key":"10993_CR36","doi-asserted-by":"crossref","DOI":"10.1186\/1742-6405-8-21","volume":"8","author":"T Mellberg","year":"2011","unstructured":"Mellberg T et al (2011) Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. AIDS Res Ther 8:1\u20136","journal-title":"AIDS Res Ther"},{"issue":"2","key":"10993_CR37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1021\/acsabm.4c01544","volume":"8","author":"M Zhao","year":"2025","unstructured":"Zhao M et al (2025) Excision of HIV-1 provirus in human primary cells with nanocapsuled TALEN proteins. ACS Appl Bio Mater 8(2):1227\u20131239","journal-title":"ACS Appl Bio Mater"},{"issue":"27","key":"10993_CR38","volume":"103","author":"Alum EU","year":"2024","unstructured":"Alum EU et al (2024) Toward a cure - Advancing hiv\/aids treatment modalities beyond antiretroviral therapy: A review. Medicine 103(27):e38768","journal-title":"Medicine"},{"key":"10993_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136311","author":"K Yu","year":"2025","unstructured":"Yu K, Liu H, Pan T (2025) HIV-1 tat: molecular switch in viral persistence and emerging technologies for functional cure. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26136311","journal-title":"Int J Mol Sci"},{"key":"10993_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060636","author":"A Banda","year":"2024","unstructured":"Banda A et al (2024) Precision in action: the role of clustered regularly interspaced short palindromic repeats\/cas in gene therapies. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines12060636","journal-title":"Vaccines (Basel)"},{"key":"10993_CR41","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00439-016-1678-2","volume":"135","author":"R Benjamin","year":"2016","unstructured":"Benjamin R et al (2016) TALEN gene editing takes aim on HIV. Hum Genet 135:1059\u20131070","journal-title":"Hum Genet"},{"issue":"7","key":"10993_CR42","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/bit.24890","volume":"110","author":"N Sun","year":"2013","unstructured":"Sun N, Zhao H (2013) Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. Biotechnol Bioeng 110(7):1811\u20131821","journal-title":"Biotechnol Bioeng"},{"key":"10993_CR43","doi-asserted-by":"crossref","unstructured":"Zubair A et al (2025) Current challenges with highly active antiretroviral therapy and new hope and horizon with CRISPR-CAS9 technology for HIV treatment, vol 105. Chemical Biology & Drug Design, p e70121. 5","DOI":"10.1111\/cbdd.70121"},{"issue":"2","key":"10993_CR44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/QAI.0000000000001190","volume":"74","author":"B Shi","year":"2017","unstructured":"Shi B et al (2017) TALEN-mediated knockout of CCR5 confers protection against infection of human immunodeficiency virus. JAIDS J Acquir Immune Defic Syndr 74(2):229\u2013241","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"10993_CR45","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/srep06409","volume":"4","author":"U Mock","year":"2014","unstructured":"Mock U et al (2014) Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. Sci Rep 4(1):6409","journal-title":"Sci Rep"},{"issue":"5","key":"10993_CR46","doi-asserted-by":"crossref","first-page":"e0125652","DOI":"10.1371\/journal.pone.0125652","volume":"10","author":"CL Strong","year":"2015","unstructured":"Strong CL et al (2015) Damaging the integrated HIV proviral DNA with TALENs. PLoS ONE 10(5):e0125652","journal-title":"PLoS ONE"},{"issue":"17","key":"10993_CR47","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1128\/JVI.01397-14","volume":"88","author":"HJ Fadel","year":"2014","unstructured":"Fadel HJ et al (2014) TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. J Virol 88(17):9704\u20139717","journal-title":"J Virol"},{"key":"10993_CR48","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.4c01544","author":"M Zhao","year":"2025","unstructured":"Zhao M et al (2025) Excision of HIV-1 provirus in human primary cells with nanocapsuled TALEN proteins. ACS Appl Bio Mater. https:\/\/doi.org\/10.1021\/acsabm.4c01544","journal-title":"ACS Appl Bio Mater"},{"issue":"1","key":"10993_CR49","first-page":"100","volume":"37","author":"P Barnett","year":"2018","unstructured":"Barnett P (2018) Transcription activator like effector nucleases (TALENs): a new, important, and versatile gene editing technique with a growing literature. Sci Technol Libr 37(1):100\u2013112","journal-title":"Sci Technol Libr"},{"issue":"4","key":"10993_CR50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14737159.2022.2065194","volume":"22","author":"E Behboudi","year":"2022","unstructured":"Behboudi E et al (2022) Transcription activator-like effector nuclease (TALEN) as a promising diagnostic approach for COVID-19. Expert Rev Mol Diagn 22(4):395\u2013397","journal-title":"Expert Rev Mol Diagn"},{"key":"10993_CR51","doi-asserted-by":"crossref","first-page":"1590690","DOI":"10.3389\/fimmu.2025.1590690","volume":"16","author":"JW Wang","year":"2025","unstructured":"Wang JW, Liu JH, Xun JJ (2025) CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions. Front Immunol 16:1590690","journal-title":"Front Immunol"},{"issue":"2","key":"10993_CR52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12033-024-01070-4","volume":"67","author":"O Volodina","year":"2025","unstructured":"Volodina O, Smirnikhina S (2025) The future of gene therapy: a review of in vivo and ex vivo delivery methods for genome editing-based therapies. Mol Biotechnol 67(2):425\u2013437","journal-title":"Mol Biotechnol"},{"issue":"1","key":"10993_CR53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12977-021-00581-1","volume":"18","author":"J Xun","year":"2021","unstructured":"Xun J et al (2021) Editing out HIV: application of gene editing technology to achieve functional cure. Retrovirology 18(1):39","journal-title":"Retrovirology"},{"issue":"5","key":"10993_CR54","doi-asserted-by":"crossref","DOI":"10.3390\/microbiolres16050104","volume":"16","author":"F Nouri","year":"2025","unstructured":"Nouri F et al (2025) Progress in CRISPR technology for antiviral treatments: genome editing as a potential cure for chronic viral infections. Microbiol Res 16(5):104","journal-title":"Microbiol Res"},{"issue":"38","key":"10993_CR55","doi-asserted-by":"crossref","first-page":"15834","DOI":"10.1073\/pnas.1101676108","volume":"108","author":"Y Zhu","year":"2011","unstructured":"Zhu Y et al (2011) Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation. Proc Natl Acad Sci U S A 108(38):15834\u201315839","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10993_CR56","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2419489122","volume":"122","author":"R Nchioua","year":"2025","unstructured":"Nchioua R et al (2025) Host ZAP activity correlates with the levels of CpG suppression in primate lentiviruses. Proc Natl Acad Sci U S A 122(15):e2419489122","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10993_CR57","doi-asserted-by":"crossref","unstructured":"Kmiec D et al (2024) HIV-2 evades restriction by ZAP through adaptations in the U3 LTR region despite increased CpG levels. bioRxiv, : p. 2024.10. 13.618097","DOI":"10.1101\/2024.10.13.618097"},{"issue":"3","key":"10993_CR58","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","volume":"24","author":"ML Maeder","year":"2016","unstructured":"Maeder ML, Gersbach CA (2016) Genome-editing technologies for gene and cell therapy. Mol Ther 24(3):430\u2013446","journal-title":"Mol Ther"},{"issue":"8","key":"10993_CR59","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.1663","volume":"28","author":"N Holt","year":"2010","unstructured":"Holt N et al (2010) Human hematopoietic stem\/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28(8):839\u2013847","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10993_CR60","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nbt1410","volume":"26","author":"EE Perez","year":"2008","unstructured":"Perez EE et al (2008) Establishment of HIV-1 resistance in CD4\u2009+\u2009T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26(7):808\u2013816","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10993_CR61","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P et al (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370(10):901\u2013910","journal-title":"N Engl J Med"},{"key":"10993_CR62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtn.2018.04.014","volume":"12","author":"H Ji","year":"2018","unstructured":"Ji H et al (2018) Zinc-finger nucleases induced by HIV-1 Tat excise HIV-1 from the host genome in infected and latently infected cells. Mol Ther Nucleic Acids 12:67\u201374","journal-title":"Mol Ther Nucleic Acids"},{"key":"10993_CR63","doi-asserted-by":"crossref","unstructured":"Tebas P et al (2024) CCR5-edited CD4\u2009+\u2009T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J Clin Investig, 131(7)","DOI":"10.1172\/JCI144486"},{"issue":"6","key":"10993_CR64","doi-asserted-by":"publisher","first-page":"01337","DOI":"10.1128\/jvi","volume":"94","author":"M Ficarelli","year":"2020","unstructured":"Ficarelli M et al (2020) CpG dinucleotides inhibit HIV-1 replication through zinc finger antiviral protein (ZAP)-dependent and-independent mechanisms. J Virol 94(6):01337\u201301319. https:\/\/doi.org\/10.1128\/jvi","journal-title":"J Virol"},{"issue":"1","key":"10993_CR65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pro.5560020102","volume":"2","author":"TL South","year":"1993","unstructured":"South TL, Summers MF (1993) Zinc-and sequence\u2010dependent binding to nucleic acids by the N\u2010terminal zinc finger of the HIV\u20101 nucleocapsid protein: NMR structure of the complex with the Psi\u2010site analog, dACGCC. Protein Sci 2(1):3\u201319","journal-title":"Protein Sci"},{"issue":"7","key":"10993_CR66","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1128\/jvi.64.7.3207-3211.1990","volume":"64","author":"RJ Gorelick","year":"1990","unstructured":"Gorelick RJ et al (1990) Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J Virol 64(7):3207\u20133211","journal-title":"J Virol"},{"issue":"5239","key":"10993_CR67","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1126\/science.270.5239.1194","volume":"270","author":"WG Rice","year":"1995","unstructured":"Rice WG et al (1995) Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270(5239):1194\u20131197","journal-title":"Science"},{"issue":"2","key":"10993_CR68","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2095-3119(17)61748-9","volume":"17","author":"L Hui","year":"2018","unstructured":"Hui L et al (2018) Comparing successful gene knock-in efficiencies of CRISPR\/Cas9 with ZFNs and TALENs gene editing systems in bovine and dairy goat fetal fibroblasts. J Integr Agric 17(2):406\u2013414","journal-title":"J Integr Agric"},{"issue":"10","key":"10993_CR69","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1172\/JCI72992","volume":"124","author":"RM Gupta","year":"2014","unstructured":"Gupta RM, Musunuru K (2014) Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest 124(10):4154\u20134161","journal-title":"J Clin Invest"},{"key":"10993_CR70","doi-asserted-by":"crossref","unstructured":"Franic D, Dobrinic P, Korac P (2019) Key achievements in gene therapy development and its promising progress with gene editing tools (ZFN, TALEN, CRISPR\/CAS9). Molecular and experimental biology in medicine. 2(1):1\u20139","DOI":"10.33602\/mebm.2.1.1"},{"issue":"1","key":"10993_CR71","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ctm2.34","volume":"10","author":"N Zheng","year":"2020","unstructured":"Zheng N, Li L, Wang X (2020) Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems. Clin Transl Med 10(1):412\u2013426","journal-title":"Clin Transl Med"},{"issue":"4","key":"10993_CR72","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ymthe.2019.01.014","volume":"27","author":"HX Zhang","year":"2019","unstructured":"Zhang HX, Zhang Y, Yin H (2019) Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Mol Ther 27(4):735\u2013746","journal-title":"Mol Ther"},{"key":"10993_CR73","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez Castro N et al (2021) Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies. Int J Mol Sci, 22(19)","DOI":"10.3390\/ijms221910355"},{"key":"10993_CR74","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2020.613252","volume":"2","author":"G Blattner","year":"2020","unstructured":"Blattner G et al (2020) Gene editing and genotoxicity: targeting the off-targets. Front Genome Ed 2:613252","journal-title":"Front Genome Ed"},{"key":"10993_CR75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2014.12.036","volume":"205","author":"QU Ain","year":"2015","unstructured":"Ain QU, Chung JY, Kim Y-H (2015) Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. J Control Release 205:120\u2013127","journal-title":"J Control Release"},{"issue":"1","key":"10993_CR76","volume":"5","author":"H Li","year":"2020","unstructured":"Li H et al (2020) Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther 5(1):1","journal-title":"Signal Transduct Target Ther"},{"key":"10993_CR77","unstructured":"Rafiq AR (2024) Genomic editing techniques for ensuring food security: CRISPR cas, TALEN, ZFN, RNAi and mutagenesis. J Pure Appl Agric, 9(2)"},{"key":"10993_CR78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-0716-2301-5_2","volume":"2495","author":"Y Shamshirgaran","year":"2022","unstructured":"Shamshirgaran Y et al (2022) Tools for efficient genome editing; ZFN, TALEN, and CRISPR. Methods Mol Biol 2495:29\u201346","journal-title":"Methods Mol Biol"},{"key":"10993_CR79","doi-asserted-by":"crossref","unstructured":"Chang AY (2022) Genome engineering with CRISPR\/Cas9, zfns, and TALENs. CRISPR genome surgery in stem cells and disease tissues. Elsevier, pp 39\u201345","DOI":"10.1016\/B978-0-12-817876-8.00009-7"},{"issue":"4","key":"10993_CR80","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1534\/genetics.111.131433","volume":"188","author":"D Carroll","year":"2011","unstructured":"Carroll D (2011) Genome engineering with zinc-finger nucleases. Genetics 188(4):773\u2013782","journal-title":"Genetics"},{"key":"10993_CR81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144486","author":"P Tebas","year":"2021","unstructured":"Tebas P et al (2021) CCR5-edited CD4\u2009+\u2009T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI144486","journal-title":"J Clin Invest"},{"issue":"12","key":"10993_CR82","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/ijbs.98029","volume":"20","author":"R Shao","year":"2024","unstructured":"Shao R et al (2024) Versatility of the zinc-finger antiviral protein (ZAP) as a modulator of viral infections. Int J Biol Sci 20(12):4585\u20134600","journal-title":"Int J Biol Sci"},{"key":"10993_CR83","volume":"3","author":"DL DiGiusto","year":"2016","unstructured":"DiGiusto DL et al (2016) Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem\/progenitor cells. Mol Ther 3:16067","journal-title":"Mol Ther"},{"issue":"9","key":"10993_CR84","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41434-021-00259-5","volume":"28","author":"LI Schwarze","year":"2021","unstructured":"Schwarze LI et al (2021) Automated production of CCR5-negative CD4(+)-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients. Gene Ther 28(9):572\u2013587","journal-title":"Gene Ther"},{"issue":"13","key":"10993_CR85","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","volume":"381","author":"L Xu","year":"2019","unstructured":"Xu L et al (2019) CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med 381(13):1240\u20131247","journal-title":"N Engl J Med"},{"issue":"1","key":"10993_CR86","doi-asserted-by":"crossref","DOI":"10.1007\/s10142-025-01613-1","volume":"25","author":"HM Hassan","year":"2025","unstructured":"Hassan HM et al (2025) New hope and promise with CRISPR-Cas9 technology for the treatment of HIV. Funct Integr Genomics 25(1):108","journal-title":"Funct Integr Genomics"},{"issue":"3","key":"10993_CR87","doi-asserted-by":"crossref","first-page":"e0317382","DOI":"10.1371\/journal.pone.0317382","volume":"20","author":"A Zubair","year":"2025","unstructured":"Zubair A et al (2025) Targeting HIV-1 conserved regions: an immunoinformatic pathway to vaccine innovation for the Asia. PLoS ONE 20(3):e0317382","journal-title":"PLoS ONE"},{"key":"10993_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020493","author":"M Lanzafame","year":"2025","unstructured":"Lanzafame M, Mori G, Vento S (2025) Advances in HIV treatment: long-acting antiretrovirals and the path toward a cure. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13020493","journal-title":"Biomedicines"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10993-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10993-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10993-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T05:05:06Z","timestamp":1766898306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10993-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10993"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10993-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"5 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"948"}}